ChemicalBook > CAS DataBase List > Fosphenytoin sodium

Fosphenytoin sodium

Product Name
Fosphenytoin sodium
CAS No.
92134-98-0
Chemical Name
Fosphenytoin sodium
Synonyms
CI 982;Cetebyx;ACC-9653;FOSPENYTOIN;ACC 9653-010;Pro-Epanutin;FOSPHENYTOIN SODIUM;Fosphenytion SodiuM;Fosphenytoin SodiuM USP;FOSPHENYTOIN DISODIUM SALT
CBNumber
CB4692780
Molecular Formula
C16H16N2NaO6P
Formula Weight
386.28
MOL File
92134-98-0.mol
More
Less

Fosphenytoin sodium Property

Melting point:
220° (softens)
storage temp. 
Inert atmosphere,2-8°C
solubility 
H2O: ≥15mg/mL
form 
powder
color 
white to tan
More
Less

Safety

Hazard Codes 
T
Risk Statements 
45-61-22
Safety Statements 
53-36/37-45
RIDADR 
UN 2811 6.1 / PGIII
WGK Germany 
3
HS Code 
2933290000
Toxicity
LD50 in mice, rats (mg/kg): 234, 363 i.v. (Smith)
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Danger
Hazard statements

H302Harmful if swallowed

H350May cause cancer

H360May damage fertility or the unborn child

Precautionary statements

P201Obtain special instructions before use.

P308+P313IF exposed or concerned: Get medical advice/attention.

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
SML0117
Product name
Fosphenytoin disodium salt hydrate
Purity
≥98% (HPLC)
Packaging
5mg
Price
$163
Updated
2024/03/01
Sigma-Aldrich
Product number
F-078
Product name
Fosphenytoindisodiumsaltsolution
Purity
1?mg/mLinmethanol((asphosphate)),certifiedreferencematerial,ampuleof1?
Packaging
1ML
Price
$108
Updated
2024/03/01
Sigma-Aldrich
Product number
1286366
Product name
Fosphenytoin sodium
Packaging
350mg
Price
$856
Updated
2024/03/01
Cayman Chemical
Product number
23889
Product name
Fosphenytoin (sodium salt)
Purity
≥98%
Packaging
50mg
Price
$44
Updated
2024/03/01
Cayman Chemical
Product number
23889
Product name
Fosphenytoin (sodium salt)
Purity
≥98%
Packaging
100mg
Price
$84
Updated
2024/03/01
More
Less

Fosphenytoin sodium Chemical Properties,Usage,Production

Originator

Cerebyx,Pfizer

Uses

PDE3 (phosphodiesterase 3) inhibitor

Uses

Anti epileptic

Uses

Fosphenytoin sodium is used in the treatment of epileptic seizures.

Manufacturing Process

By action of formaldehyde and hydrochloric acid on 5,5-diphenylhydantoin was prepared 3-hydroxymethyl-5,5-diphenyl-imidazolidine-2,4-dione which was converted by action PCl3 to 3-chloromethyl-5,5-diphenyl-imidazolidine-2,4- dione by action PCl3. Then the chlorine atom was substituted on P(O)(OBz)Ogroup by action of argentum salt of phosphoric acid dibenzyl ester. Removal of the protecting groups by hydrogenolysis gives the 2,4-imidazolidinedione, 5,5- diphenyl-3-((phosphonooxy)methyl)- (fosphenytoin).
In practice it is usually used as sodium salt.

brand name

Cerebyx (Parke-Davis).

Therapeutic Function

Antiepileptic, Anticonvulsant

Clinical Use

Control of status epilepticus
Seizures associated with neurosurgery or head injury when oral phenytoin is not possible

Drug interactions

Potentially hazardous interactions with other drugs Aminophylline and theophylline: concentration of both drugs reduced with aminophylline and theophylline. Analgesics: enhanced effect with NSAIDs; metabolism of methadone accelerated; possibly increases pethidine toxicity. Anthelmintics: concentration of albendazole and praziquantel reduced; concentration of fosphenytoin possibly increased by levamisole. Anti-arrhythmics: increased concentration with amiodarone; concentration of disopyramide and possibly dronedarone reduced - avoid with dronedarone. Antibacterials: level increased by clarithromycin, chloramphenicol, isoniazid, metronidazole, sulphonamides and trimethoprim (+ antifolate effect); concentration increased or decreased by ciprofloxacin; concentration of bedaquiline, doxycycline and telithromycin reduced - avoid with telithromycin; concentration reduced by rifamycins.
Anticoagulants: increased metabolism of coumarins (reduced effect but also reports of enhancement); possibly reduced apixaban, dabigatran, edoxaban and rivaroxaban concentration - avoid with dabigatran.
Antidepressants: antagonise anticonvulsant effect; concentration increased by fluoxetine and fluvoxamine and possibly sertraline; concentration of mianserin, mirtazapine and paroxetine and possibly tricyclics reduced; concentration reduced by St John’s wort - avoid.
Antiepileptics: concentration of both drugs reduced with carbamazepine, concentration may also be increased by carbamazepine, eslicarbazepine, ethosuximide, oxcarbazepine, stripentol and topiramate; concentration of ethosuximide, active oxcarbazepine metabolite, retigabine, rufinamide (concentration of phenytoin possibly increased), topiramate and valproate possibly reduced; concentration of eslicarbazepine, ethosuximide, lamotrigine, perampanel, tiagabine and zonisamide reduced; concentration of phenobarbital often
increased; phenobarbital and valproate may alter concentration; concentration reduced by vigabatrin.
Antifungals: concentration of ketoconazole, itraconazole, posaconazole, voriconazole and possibly isavuconazole and caspofungin reduced - avoid with isavuconazole and itraconazole, increase voriconazole dose and possibly caspofungin; levels increased by fluconazole, miconazole and voriconazole - consider reducing fosphenytoin dose.
Antimalarials: avoid with piperaquine with artenimol, mefloquine and pyrimethamine - antagonise anticonvulsant effect; increased antifolate effect with pyrimethamine.
Antipsychotics: antagonise anticonvulsant effect; possibly reduced aripiprazole concentration - increase aripiprazole dose; metabolism of clozapine, haloperidol, quetiapine and sertindole increased; concentration increased or decreased with chlorpromazine; possibly reduces lurasidone concentration - avoid.
Antivirals: possibly reduced concentration of abacavir, boceprevir, daclatasvir, darunavir, dasabuvir, dolutegravir, indinavir, lopinavir, ombitasvir, paritaprevir, ritonavir, saquinavir and simeprevir - avoid with boceprevir, daclatasvir, dasabuvir, ombitasvir, paritaprevir and simeprevir; rilpivirine reduced - avoid; concentration possibly increased by indinavir and ritonavir; concentration increased or decreased with zidovudine; avoid with elvitegravir,
etravirine and telaprevir.
Apremilast: concentration of apremilast reduced - avoid.
Calcium-channel blockers: levels increased by diltiazem; concentration of diltiazem, felodipine, isradipine, nimodipine and verapamil reduced; avoid with isradipine and nimodipine.
Cannabis extract: concentration possibly reduced by phenytoin - avoid.
Ciclosporin: reduced ciclosporin levels.
Cobicistat: concentration of cobicistat possibly reduced.
Corticosteroids: metabolism accelerated (effect reduced)
. Cytotoxics: metabolism possibly inhibited by
fluorouracil; increased antifolate effect with methotrexate; reduced fosphenytoin absorption; concentration of busulfan, cabozantinib, ceritinib, eribulin, etoposide and imatinib reduced - avoid with cabozantib, ceritinib and imatinib; concentration possibly reduced by bosutinib, cisplatin ibrutinib and idelalisib - avoid with ibrutinib and idelalisib; possibly reduced concentration of axitinib, increase axitinib dose; possibly reduced concentration of crizotinib - avoid; avoid with cabazitaxel, gefitinib, lapatinib, olaparib, panobinostat, vemurafenib and vismodegib; concentration of irinotecan and its active metabolite reduced.
Dexrazoxane: absorption of fosphenytoin possibly reduced.
Disulfiram: metabolism of fosphenytoin inhibited. Diuretics: concentration increased by acetazolamide; concentration of eplerenone reduced - avoid; increased risk of osteomalacia with carbonic anhydrses inhibitors; antagonises effect of furosemide.
Guanfacine: concentration of guanfacine possibly reduced - increase dose of guanfacine.
Hormone antagonists: possibly reduced concentration of abiraterone - avoid; metabolism of toremifene accelerated.
Ivacaftor: concentration of ivacaftor possibly reduced - avoid.
Muscle relaxants: long-term use of phenytoin reduces effects of non-depolarising muscle relaxants, but acute use may enhance effects.
Oestrogens and progestogens: metabolism increased (reduced contraceptive effect).
Orlistat: possibly increased risk of convulsions.
Sulfinpyrazone: concentration increased by sulfinpyrazone.
Ulcer-healing drugs: metabolism inhibited by cimetidine; absorption reduced by sucralfate;
enhanced effect with esomeprazole and omeprazole.
Ulipristal: contraceptive effect possibly reduced - avoid.

Metabolism

Fosphenytoin is rapidly and completely hydrolysed to phenytoin with a conversion half-life of about 15 minutes; one mmol of fosphenytoin yields one mmol of phenytoin. Phenytoin is hydroxylated in the liver to inactive metabolites chiefly 5-(4-hydroxyphenyl)-5- phenylhydantoin by an enzyme system which is saturable. Phenytoin undergoes enterohepatic recycling and is excreted in the urine, mainly as its hydroxylated metabolite, in either free or conjugated form.

Fosphenytoin sodium Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Fosphenytoin sodium Suppliers

Chengdu D-innovation Pharmaceutical Co.,LTD
Tel
028-85929779 18009044761
Email
pengxing@d-innovation.com
Country
China
ProdList
296
Advantage
58
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Fax
86-10-82849933
Email
jkinfo@jkchemical.com
Country
China
ProdList
96815
Advantage
76
Chemsky (shanghai) International Co.,Ltd
Tel
021-50135380
Email
shchemsky@sina.com
Country
China
ProdList
15402
Advantage
60
Sinopharm Chemical Reagent Co,Ltd.
Tel
86-21-63210123
Fax
86-21-63290778 86-21-63218885
Email
sj_scrc@sinopharm.com
Country
China
ProdList
9815
Advantage
79
Shanghai Sunway Pharmaceutical Technology Co., Ltd
Tel
021-51613915-820 13611835272
Fax
021 51613951
Email
mmwang@sunwaypharm.cn
Country
China
ProdList
9734
Advantage
57
Hangzhou Yuhao Chemical Technology Co., Ltd
Tel
0571-82693216
Fax
+86-571-82880190
Email
info@yuhaochemical.com
Country
China
ProdList
9387
Advantage
52
Beijing HuaMeiHuLiBiological Chemical
Tel
010-56205725
Fax
010-65763397
Email
waley188@sohu.com
Country
China
ProdList
12335
Advantage
58
9ding chemical ( Shanghai) Limited
Tel
4009209199
Fax
86-021-52271987
Email
sales@9dingchem.com
Country
China
ProdList
18209
Advantage
56
MedChemexpress LLC
Tel
021-58955995
Fax
609-228-5909
Email
sales@medchemexpress.cn
Country
United States
ProdList
4861
Advantage
58
GIHI CHEMICALS CO.,LTD
Tel
0086-571-86217390
Fax
0086-571-86217391
Email
Sales@gihichem.com
Country
China
ProdList
860
Advantage
58

92134-98-0, Fosphenytoin sodiumRelated Search:


  • 5,5-Diphenyl-3-[(phosphonooxy)methyl]-2,4-imidazolidinedione disodium salt
  • Fosphenytoin Sodium (350 mg)
  • FOSPHENYTOIN SODIUM
  • (sp-4-2)-5,5-diphenyl-3-((phosphonooxy)methyl)-2,4-imidazolidinedione disodium salt
  • FOSPENYTOIN
  • FOSPHENYTOIN DISODIUM SALT
  • 5,5-Diphenyl-3-[[[di(sodiooxy)phosphinyl]oxy]methyl]-1H-imidazole-2,4(3H,5H)-dione
  • ACC-9653
  • Fosphenytoin Sodium (250 mg)
  • Fosphenytion SodiuM
  • 5,5-Diphenyl-3-[(phosphonooxy)Methyl]-2,4-iMidazolidinedione SodiuM Salt
  • ACC 9653-010
  • Cetebyx
  • CI 982
  • Pro-Epanutin
  • Fosphenytoin SodiuM USP
  • 5,5-Diphenyl-3-[(phosphonooxy)methyl]-2,4-imidazolidinedione disodium salt hydrate
  • Fosphenytoin disodium salt hydrate
  • Fosphenytoin (sodium salt)
  • disodium (2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methyl phosphate
  • Fosphenytoin Sodium (ACC-9653)
  • Fosphenytoin Sodium (1286366)
  • Phenytoin Impurity 11(Fosphenytoin Disodium Salt)
  • isodium,(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methylphosphate
  • Sodium (2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methyl phosphate
  • 92134-98-0
  • C16H13N2O6P2Na
  • C16H13N2Na2O6P
  • C16H15N2O6P2Na
  • C16H13N2O6P2NaH2O
  • Heterocycles
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • API